ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 742,09
2,33%
Dow Jones
42 157,84
0,58%
DAX
19 238,36
1,67%
Brent Oil
70,945
-3,07%
Bitcoin
65 241,83
3,34%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) Actualités

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:JNJ
DateHeureSourceTitreSymboleSociété
23/09/202412h32IH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNYSE:JNJJohnson and Johnson
21/09/202400h53Business WireAttorneys Vow to Oppose J&J’s Third Bankruptcy AttemptNYSE:JNJJohnson and Johnson
20/09/202422h19Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
20/09/202421h43Business WireJohnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc ClaimsNYSE:JNJJohnson and Johnson
20/09/202400h54PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
17/09/202412h40IH Market NewsMicrosoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with AmazonNYSE:JNJJohnson and Johnson
16/09/202408h50PR Newswire (US)Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancerNYSE:JNJJohnson and Johnson
15/09/202408h30PR Newswire (US)New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancerNYSE:JNJJohnson and Johnson
14/09/202415h45PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancerNYSE:JNJJohnson and Johnson
14/09/202409h10PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancerNYSE:JNJJohnson and Johnson
12/09/202422h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
12/09/202400h22PR Newswire (US)TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel diseaseNYSE:JNJJohnson and Johnson
10/09/202423h15PR Newswire (US)Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)NYSE:JNJJohnson and Johnson
08/09/202419h47PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
05/09/202422h30Business WireJohnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsNYSE:JNJJohnson and Johnson
05/09/202412h11IH Market NewsQualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual ListingNYSE:JNJJohnson and Johnson
30/08/202421h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:JNJJohnson and Johnson
29/08/202420h05Edgar (US Regulatory)Form N-PX - Annual Report of proxy voting record of management investment companiesNYSE:JNJJohnson and Johnson
29/08/202414h00PR Newswire (US)Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravisNYSE:JNJJohnson and Johnson
27/08/202414h00PR Newswire (US)Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology CongressNYSE:JNJJohnson and Johnson
26/08/202414h58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:JNJJohnson and Johnson
26/08/202414h00Business WireJohnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024NYSE:JNJJohnson and Johnson
21/08/202414h12IH Market NewsWalmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest NewsNYSE:JNJJohnson and Johnson
20/08/202413h30Business WireJohnson & Johnson to Acquire V-WaveNYSE:JNJJohnson and Johnson
20/08/202413h00PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
15/08/202412h05IH Market NewsGoogle Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
15/08/202412h05IH Market NewsGoogle Forced to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
13/08/202411h43IH Market NewsDell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and MoreNYSE:JNJJohnson and Johnson
09/08/202422h35Edgar (US Regulatory)Form 13F-HR - Quarterly report filed by institutional managers, HoldingsNYSE:JNJJohnson and Johnson
07/08/202423h00PR Newswire (US)Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of MedicineNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Dernières Valeurs Consultées

EU
ZSG5D
Euronext Eurozone SBT 15...
COIN
LTBCEUR
Litbinex Coin
BOV
EUCA4F
EUCATEX PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés